Respiratory Syncytial Virus (RSV) for Health Professionals

CDC recommends RSV vaccination for all adults 75 years of age and older and for adults 50-74 who are at increased risk of severe RSV disease. Adults who could benefit from vaccination due to higher risk of severe disease caused by RSV are those with underlying medical conditions, frailty or advanced age, and residents in long-term care facilities. Eligible adults can get an RSV vaccine at any time, but the best time to get vaccinated is in late summer and early fall before RSV usually starts to spread in communities.

Vaccine resources for older adults

• CDC: Respiratory Syncytial Virus (RSV) Immunizations
• CDC: ACIP Recommendations: Respiratory Syncytial Virus (RSV) Vaccine
• CDC: Current VISs
• CDC: Clinical Overview of RSV
• CDC: Diagnostic Testing for RSV
• CDC: About V-safe
  Providers are urged to promote V-safe to adults ages 60 years and older and pregnant people 16-49 years of age who are vaccinated with RSV and have a computer, tablet, or smartphone. V-safe is a vaccine safety monitoring system that allows a person who is vaccinated to share with the CDC how they are feeling after vaccination.

Vaccination during pregnancy

• Pfizer Abrysvo is the only RSV vaccine recommended during pregnancy.
• One dose should be given during weeks 32 through 36 of pregnancy, administered September through January (to protect infants born October through March).
• No additional doses should be given in subsequent pregnancies; the infant should receive a monoclonal antibody instead.

Monoclonal antibody prophylaxis

• Nirsevimab (also known as Beyfortus) and clesrovimab (also known as Enflonsia) are a long-acting RSV monoclonal antibody recommended for infants/toddlers to prevent lower respiratory tract disease from RSV.
• Monoclonal antibodies should be given:
  • In the first week of life for infants born shortly before and during the season.
  • Shortly before the start of the RSV season for infants aged less than 8 months (October through March).
  • For nirsevimab only: Shortly before the start of the RSV season for children aged 8 to 19 months who are at increased risk of severe RSV disease or are American Indian and Alaska Native.
• The dosage is dependent on the product used:
  • Nirsevimab is weight dependent:
    • Infants less than 5kg (11 pounds) get 50mg.
    • Infants 5kg (11 pounds) and over get 100mg.
  • Clesrovimab is 105mg for all infants regardless of weight.
• The supply of monoclonal antibody products is projected to be adequate for the 2025-2026 season. Clesrovimab is not currently available for ordering on the federal contract, so is not currently available for VFC eligible children. It is expected to be available later this year.
• For more information visit Healthcare Providers: RSV Immunization for Infant and Young Children.

Vaccine resources for infant and pregnant people

• CDC: ACIP Recommendations: Respiratory Syncytial Virus (RSV) Vaccine
• CDC: Current VISs
• CDC: Respiratory Syncytial Virus (RSV) Immunizations
• Respiratory Syncytial Virus (RSV) Preventive Antibody: Immunization Information Statement (IIS)
• CDC: Clinical Overview of RSV
• CDC: Diagnostic Testing for RSV
• AAP: Nirsevemab Administration Visual Guide (PDF)
• CDC About V-safe 
  Providers are urged to promote V-safe to adults ages 50 years and older and pregnant people 16-49 years of age who are vaccinated with RSV and have a computer, tablet, or smartphone. V-safe is a vaccine safety monitoring system that allows a person who is vaccinated to share with the CDC how they are feeling after vaccination.